Seattle Genetics
Acquired
- Headquarters
- Seattle/Bothell, Washington
- Employees
- 1001–5000
- Founded
- 1998
- Business Model
- B2B
- Website
- seagen.com
- Total Funding
- $1.0B
- Valuation
- $204.8MMar 2001
- Last Round
- $1.0B Corporate RoundSep 2020
About
Seattle Genetics (later rebranded as Seagen) was a Bothell, Washington-based biotechnology company specializing in developing antibody-drug conjugates (ADCs) for cancer treatment. Founded in 1998, the company pioneered ADC technology, which links cancer-targeting antibodies to potent chemotherapy drugs, enabling precision delivery to tumor cells. Seagen was acquired by Pfizer in December 2023 for approximately $43 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account